Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,201 to 1,220 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Significance of Tumor Microenvironment Score for Breast Cancer Patients. | Biomed Res Int | 2022 | 35528180 | PubTator, text mining | PubMed |
| Construction of a necroptosis-related lncRNA signature to predict the prognosis and immune microenvironment of head and neck squamous cell carcinoma. | J Clin Lab Anal | 2022 | 35522142 | PubTator, text mining | PubMed |
| Dissecting the Role of Immune Checkpoint Regulation Patterns in Tumor Microenvironment and Prognosis of Gastric Cancer. | Front Genet | 2022 | 35518357 | PubTator, text mining | PubMed |
| Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma. | J Inflamm Res | 2022 | 35509325 | PubTator, text mining | PubMed |
| Reduced expression of lncRNA DLEU7-AS1 is a novel favorable prognostic factor in acute myeloid leukemia. | Biosci Rep | 2022 | 35506368 | PubTator, text mining | PubMed |
| SRSF3 Expression Serves as a Potential Biomarker for Prognostic and Immune Response in Pan-Cancer. | Front Oncol | 2022 | 35494088 | PubTator, text mining | PubMed |
| EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. | JCI Insight | 2022 | 35482424 | PubTator, text mining | PubMed |
| Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer. | Front Immunol | 2022 | 35479097 | PubTator, text mining | PubMed |
| Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma. | Front Immunol | 2022 | 35479067 | PubTator, text mining | PubMed |
| Decoy receptor 3 is involved in epidermal keratinocyte commitment to terminal differentiation via EGFR and PKC activation. | Exp Mol Med | 2022 | 35478210 | PubTator, text mining | PubMed |
| DNA methylation profile of liver tissue in end-stage cholestatic liver disease. | Epigenomics | 2022 | 35473391 | PubTator, text mining | PubMed |
| Programmed Cell Death-Dependent Host Defense in Ocular Herpes Simplex Virus Infection. | Front Microbiol | 2022 | 35464953 | PubTator, text mining | PubMed |
| The Status and Prospects of Epigenetics in the Treatment of Lymphoma. | Front Oncol | 2022 | 35463343 | PubTator, text mining | PubMed |
| Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. | Heredity (Edinb) | 2022 | 35459932 | PubTator, text mining | PubMed |
| Plasma Membrane-Derived Liposomes Exhibit Robust Antiviral Activity against HSV-1. | Viruses | 2022 | 35458528 | PubTator, text mining | PubMed |
| Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach. | Cancers (Basel) | 2022 | 35454765 | PubTator, text mining | PubMed |
| The Need for Standardization in Next-Generation Sequencing Studies for Classic Hodgkin Lymphoma: A Systematic Review. | Diagnostics (Basel) | 2022 | 35454013 | PubTator, text mining | PubMed |
| Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling. | PLoS One | 2022 | 35452489 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas. | Front Immunol | 2022 | 35444654 | PubTator, text mining | PubMed |
| A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs. | J Clin Lab Anal | 2022 | 35441740 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=61